Edwards Lifesciences (EW) Capital Expenditures (2009 - 2026)

Edwards Lifesciences has reported Capital Expenditures for 18 years, with the latest figure at $64.9 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 15.89% year-over-year to $64.9 million; the trailing twelve-month figure through Mar 2026 stood at $269.1 million (up 10.7% YoY), and the FY2025 full-year result was $260.2 million, up 3.09% from the prior year.
• Capital Expenditures for Q1 2026 stood at $64.9 million, down from $97.4 million in the prior quarter.
• The five-year high for Capital Expenditures was $97.4 million in Q4 2025, with the low at $43.1 million in Q2 2022.
• Average Capital Expenditures over 5 years is $63.2 million, with a median of $59.9 million recorded in 2022.
• Year-over-year, Capital Expenditures tumbled 43.6% in 2024 and surged 95.58% in 2025.
• Tracing EW's Capital Expenditures over 5 years: stood at $68.9 million in 2022, then increased by 28.16% to $88.3 million in 2023, then plunged by 43.6% to $49.8 million in 2024, then surged by 95.58% to $97.4 million in 2025, then plunged by 33.37% to $64.9 million in 2026.
• The last three Capital Expenditures figures came in at $64.9 million (Q1 2026), $97.4 million (Q4 2025), and $57.5 million (Q3 2025), per Business Quant data.

Peer Comparison